Cancer Moonshot 2.0

In 2017, a Lancet Oncology Commission on future cancer research priorities in the USA was established to build and elaborate on the recommendations made in the Blue Ribbon report; the results of this Commission were published on Nov 1, 2017.1 Since the launch of the Cancer Moonshot initiative, the NCI has implemented initiatives to advance research in immuno-oncology, cancer drug sensitivity and resistance, childhood cancers, patient engagement, cancer health disparities, and clinical implementation science, and has funded the Human Tumor Atlas Network. Numerous challenges have prevented Moonshot from reaching its full potential. [...]the landscape of cancer therapies and technologies has changed markedly since the original roadmap was developed in 2016. [...]more than just building on the momentum and progress of the past 7 years, we must expand and amplify this progress. [...]we hereby announce the formation of a team to undertake a second Moonshot Commission for The Lancet Oncology to accomplish goals left incomplete and address new challenges for this new era.